Inversion is all the rage – and it’s sparking rage, too. Companies are employing or considering the complex and controversial tax maneuver to relocate their headquarters to countries more tax-friendly than the U.S. and save bundles. Pfizer is perhaps the largest corporation to attempt inversion. (The deal fell through.) Walgreen’s and as many as 30 other deals reportedly are in the pipeline.